
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera is well positioned in the market due to their innovative technologies and strong track record, with recent approval in Japan for their MRD test and plans for global expansion. Success in their women's health and organ transplant businesses, along with a 10% increase in stock, demonstrate their potential for growth. However, external factors such as reimbursement changes and market saturation could affect their growth trajectory moving forward.
Bears say
Natera is facing a few challenges ahead. First, although Natera has been eyeing Japan as a potential growth market, the company has yet to see meaningful revenue contribution from this region, potentially indicating difficulties in penetrating this market. Second, while Natera has had success in securing Medicare coverage for its products, there may be uncertainty and potential delays in securing similar coverage from commercial payors. Lastly, while the company has seen consistent growth in Signatera's average selling price, there is a risk that this growth could stall as a result of limited opportunities for further adoption in established use cases.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares